Arca
Skip to content

Amyotrophic lateral sclerosis (als)

Drug research and approvals for amyotrophic lateral sclerosis (als): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 174 studies of amyotrophic lateral sclerosis (als) are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 8 approved and 134 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 174
  • Trials authorized in Canada: 57
  • FDA orphan approvals: 8
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 174 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 57; search them all in Canada trials
Apr 1, 2026A master protocol for open-label extension studies to evaluate the long term safety and tolerability of interventions in various stages of clinical development…LY4256984Eli LillyOngoing
Jan 30, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine in participants with amyotrophic lateral…PRIDOPIDINEPRILENIA THERAPEUTICS B.V.Ongoing
Dec 19, 2025Phase 2, randomized, double-blind, placebo-controlled, multi-center, 24-week study with additional 24-week blinded active extension to evaluate the safety and…COYA 302COYA THERAPEUTICSOngoing
Oct 8, 2025A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and…USNOFLAST (ZYIL1)ZYDUS THERAPEUTICS INC.Ongoing
Oct 16, 2024Targeting neuroinflammation with enhanced delivery of intravenous immunoglobulin to the motor cortex using next generation dome helmet focused ultrasound in…PRIVIGEN (IMMUNOGLOBULIN (HUMAN)) / DEFINITY (PERFLUTREN)SUNNYBROOK RESEARCH INSTITUTEOngoing
Oct 2, 2024A phase 2, randomized, double-blind, placebo-controlled parallel group study of vhb937 in amyotrophic lateral sclerosis (als) over 40 weeks followed by an…VHB937Novartis Pharmaceuticals CorporationClosed
Jun 26, 2024A phase 2a, double-blinded, randomized, placebo-controlled, and active-treatment extension study to assess the safety, tolerability, efficacy,…ARGX-119argenx US, Inc.Closed
Apr 5, 2024First in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered…ALN-SODRegeneronOngoing
Nov 16, 2023A phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of single ascending…PROSETIN (COL-001)PROJENX, INC.Ongoing
Oct 13, 2023A phase 1b, open-label, multiple ascending dose, multicenter study of vrg50635 in participants with sporadic and familial amyotrophic lateral sclerosis…VRG50635VERGE GENOMICSOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 142
Apr 25, 2023Qalsodytreatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) geneBiogen Inc.Approved
Sep 29, 2022RelyvrioTreatment of amyotrophic lateral sclerosis (ALS) in adultsAmylyx Pharmaceuticals, Inc.Approved
May 12, 2022Radicava ORSTreatment of amyotrophic lateral sclerosis (ALS)Tanabe Pharma America Inc.Approved
Dec 13, 2019TiglutikTIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).Italfarmaco SpAApproved
Nov 22, 2019EXSERVANEXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).Aquestive TherapeuticsApproved
Sep 5, 2018TiglutikTIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).Italfarmaco SpAApproved
May 5, 2017RadicavaTreatment of amyotrophic lateral sclerosis (ALS)Tanabe Pharma America Inc.Approved
Dec 12, 1995RilutekTreatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.Rhone-Poulenc Rorer Pharmaceuticals, Inc.Approved
Sep 8, 2026stem cell-derived protein complex derived from the…treatment of amyotrophic lateral sclerosisDarwin Origin (Hubei) Biopharmaceutical Co., Ltd.Designated
May 29, 2026mitogen-activated protein kinase (MAPK)/extracellular…treatment of amyotrophic lateral sclerosisPasithea Therapeutics Corp.Designated
Apr 6, 2026a selective transactive response DNA-binding protein 43…treatment of amyotrophic lateral sclerosisTalengen America LimitedDesignated
Mar 2, 2026meloxicamtreatment of amyotrophic lateral sclerosisAniMusCure Inc.Designated
Feb 27, 2026alpha-lipoic acidtreatment of amyotrophic lateral sclerosisWenling City Innovation Biotechnology Co., Ltd.Designated
Feb 23, 2026L-methionine-S,R-sulfoximinetreatment of amyotrophic lateral sclerosisWilliam S. BrusilowDesignated
Oct 17, 2025allogeneic, cord blood-derived T regulatory cells that…treatment of amyotrophic lateral sclerosisCellenkos IncDesignated

Medicines Authorised in the EU

Newest first
May 29, 2024Qalsodytofersen · orphanBiogen Netherlands B.V.EMA ↗
May 7, 2012Riluzole ZentivariluzoleZentiva k.s.EMA ↗
Jun 10, 1996RilutekriluzoleSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.